Agile Therapeutics,Inc. (NASDAQ:AGRX) Files An 8-K Other Events
Item8.01.Other Events.
On April11, 2017, Agile Therapeutics,Inc. (Agile) issued a press
release announcing that Agile has received the final meeting
minutes from the U.S. Food and Drug Administration (FDA) for its
recent pre-New Drug Application (NDA) submission meeting on its
lead product candidate, Twirla, a once-weekly prescription
contraceptive patch.
A copy of Agiles press release is attached hereto as Exhibit99.1
and is hereby incorporated by reference herein.
Item 9.01. Financial Statements and
Exhibits.
(d) Exhibits.
|
Exhibit Number |
|
Description |
|
99.1 |
Agile Therapeutics,Inc. Press Release dated April11, 2017 |
About Agile Therapeutics, Inc. (NASDAQ:AGRX)
Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period. Agile Therapeutics, Inc. (NASDAQ:AGRX) Recent Trading Information
Agile Therapeutics, Inc. (NASDAQ:AGRX) closed its last trading session up +0.15 at 3.11 with 172,992 shares trading hands.